Association of Panic Disorder, Generalized Anxiety Disorder, and Benzodiazepine Treatment During Pregnancy With Risk of Adverse Birth Outcomes | Anxiety Disorders | JAMA Psychiatry | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 34.239.150.57. Please contact the publisher to request reinstatement.
1.
Goodman  JH, Chenausky  KL, Freeman  MP.  Anxiety disorders during pregnancy: a systematic review.  J Clin Psychiatry. 2014;75(10):e1153-e1184.PubMedGoogle ScholarCrossref
2.
Gentile  S.  Untreated depression during pregnancy: short- and long-term effects in offspring: a systematic review.  Neuroscience. 2017;342:154-166.PubMedGoogle ScholarCrossref
3.
Chen  YH, Lin  HC, Lee  HC.  Pregnancy outcomes among women with panic disorder—do panic attacks during pregnancy matter?  J Affect Disord. 2010;120(1-3):258-262.PubMedGoogle ScholarCrossref
4.
Bánhidy  F, Acs  N, Puhó  E, Czeizel  AE.  Association between maternal panic disorders and pregnancy complications and delivery outcomes.  Eur J Obstet Gynecol Reprod Biol. 2006;124(1):47-52.PubMedGoogle ScholarCrossref
5.
Uguz  F, Sahingoz  M, Sonmez  EO,  et al.  The effects of maternal major depression, generalized anxiety disorder, and panic disorder on birth weight and gestational age: a comparative study.  J Psychosom Res. 2013;75(1):87-89.PubMedGoogle ScholarCrossref
6.
Pavlov  M, Steiner  N, Kessous  R, Weintraub  AY, Sheiner  E.  Obstetric and neonatal outcome in patients with anxiety disorders.  J Matern Fetal Neonatal Med. 2014;27(13):1339-1342.PubMedGoogle ScholarCrossref
7.
Yonkers  KA, Norwitz  ER, Smith  MV,  et al.  Depression and serotonin reuptake inhibitor treatment as risk factors for preterm birth.  Epidemiology. 2012;23(5):677-685.PubMedGoogle ScholarCrossref
8.
Huybrechts  KF, Sanghani  RS, Avorn  J, Urato  AC.  Preterm birth and antidepressant medication use during pregnancy: a systematic review and meta-analysis.  PLoS One. 2014;9(3):e92778.PubMedGoogle ScholarCrossref
9.
Eke  AC, Saccone  G, Berghella  V.  Selective serotonin reuptake inhibitor (SSRI) use during pregnancy and risk of preterm birth: a systematic review and meta-analysis.  BJOG. 2016;123(12):1900-1907.PubMedGoogle ScholarCrossref
10.
Sujan  AC, Rickert  ME, Öberg  AS,  et al.  Associations of maternal antidepressant use during the first trimester of pregnancy with preterm birth, small for gestational age, autism spectrum disorder, and attention-deficit/hyperactivity disorder in offspring.  JAMA. 2017;317(15):1553-1562.PubMedGoogle ScholarCrossref
11.
El Marroun  H, Jaddoe  VW, Hudziak  JJ,  et al.  Maternal use of selective serotonin reuptake inhibitors, fetal growth, and risk of adverse birth outcomes.  Arch Gen Psychiatry. 2012;69(7):706-714.PubMedGoogle ScholarCrossref
12.
Reis  M, Källén  B.  Delivery outcome after maternal use of antidepressant drugs in pregnancy: an update using Swedish data.  Psychol Med. 2010;40(10):1723-1733.PubMedGoogle ScholarCrossref
13.
Malm  H, Klaukka  T, Neuvonen  PJ.  Risks associated with selective serotonin reuptake inhibitors in pregnancy.  Obstet Gynecol. 2005;106(6):1289-1296.PubMedGoogle ScholarCrossref
14.
Nordeng  H, van Gelder  MM, Spigset  O, Koren  G, Einarson  A, Eberhard-Gran  M.  Pregnancy outcome after exposure to antidepressants and the role of maternal depression: results from the Norwegian Mother and Child Cohort Study.  J Clin Psychopharmacol. 2012;32(2):186-194.PubMedGoogle ScholarCrossref
15.
Grigoriadis  S, VonderPorten  EH, Mamisashvili  L,  et al.  The effect of prenatal antidepressant exposure on neonatal adaptation: a systematic review and meta-analysis.  J Clin Psychiatry. 2013;74(4):e309-e320.PubMedGoogle ScholarCrossref
16.
De Ocampo  MPG, Araneta  MRG, Macera  CA, Alcaraz  JE, Moore  TR, Chambers  CD.  Risk of gestational hypertension and preeclampsia in women who discontinued or continued antidepressant medication use during pregnancy.  Arch Womens Ment Health. 2016;19(6):1051-1061.PubMedGoogle ScholarCrossref
17.
De Vera  MA, Bérard  A.  Antidepressant use during pregnancy and the risk of pregnancy-induced hypertension.  Br J Clin Pharmacol. 2012;74(2):362-369.PubMedGoogle ScholarCrossref
18.
Toh  S, Mitchell  AA, Louik  C, Werler  MM, Chambers  CD, Hernández-Díaz  S.  Selective serotonin reuptake inhibitor use and risk of gestational hypertension.  Am J Psychiatry. 2009;166(3):320-328.PubMedGoogle ScholarCrossref
19.
Avalos  LA, Chen  H, Li  D-K.  Antidepressant medication use, depression, and the risk of preeclampsia.  CNS Spectr. 2015;20(1):39-47.PubMedGoogle ScholarCrossref
20.
Malm  H, Sourander  A, Gissler  M,  et al.  Pregnancy complications following prenatal exposure to SSRIs or maternal psychiatric disorders: results from population-based national register data.  Am J Psychiatry. 2015;172(12):1224-1232.PubMedGoogle ScholarCrossref
21.
Maschi  S, Clavenna  A, Campi  R, Schiavetti  B, Bernat  M, Bonati  M.  Neonatal outcome following pregnancy exposure to antidepressants: a prospective controlled cohort study.  BJOG. 2008;115(2):283-289.PubMedGoogle ScholarCrossref
22.
Calderon-Margalit  R, Qiu  C, Ornoy  A, Siscovick  DS, Williams  MA.  Risk of preterm delivery and other adverse perinatal outcomes in relation to maternal use of psychotropic medications during pregnancy.  Am J Obstet Gynecol. 2009;201(6):579.e1-579.e8.PubMedGoogle ScholarCrossref
23.
Källén  B, Reis  M.  Neonatal complications after maternal concomitant use of SSRI and other central nervous system active drugs during the second or third trimester of pregnancy.  J Clin Psychopharmacol. 2012;32(5):608-614.PubMedGoogle ScholarCrossref
24.
Crump  C, Winkleby  MA, Sundquist  K, Sundquist  J.  Preterm birth and psychiatric medication prescription in young adulthood: a Swedish national cohort study.  Int J Epidemiol. 2010;39(6):1522-1530.PubMedGoogle ScholarCrossref
25.
Wikner  BN, Stiller  CO, Bergman  U, Asker  C, Källén  B.  Use of benzodiazepines and benzodiazepine receptor agonists during pregnancy: neonatal outcome and congenital malformations.  Pharmacoepidemiol Drug Saf. 2007;16(11):1203-1210.PubMedGoogle ScholarCrossref
26.
Yonkers  KA, Smith  MV, Forray  A,  et al.  Pregnant women with posttraumatic stress disorder and risk of preterm birth.  JAMA Psychiatry. 2014;71(8):897-904.PubMedGoogle ScholarCrossref
27.
Wittchen  HU.  Reliability and validity studies of the WHO–Composite International Diagnostic Interview (CIDI): a critical review.  J Psychiatr Res. 1994;28(1):57-84.PubMedGoogle ScholarCrossref
28.
Kessler  RC, Nelson  CB, McGonagle  KA, Liu  J, Swartz  M, Blazer  DG.  Comorbidity of DSM-III-R major depressive disorder in the general population: results from the US National Comorbidity Survey.  Br J Psychiatry Suppl. 1996;168(30):17-30.PubMedGoogle Scholar
29.
Kessler  RC, Ustün  TB.  The World Mental Health (WMH) Survey Initiative version of the World Health Organization (WHO) Composite International Diagnostic Interview (CIDI).  Int J Methods Psychiatr Res. 2004;13(2):93-121.PubMedGoogle ScholarCrossref
30.
Kessler  RC, Avenevoli  S, Costello  EJ,  et al.  National comorbidity survey replication adolescent supplement (NCS-A), II: overview and design.  J Am Acad Child Adolesc Psychiatry. 2009;48(4):380-385.PubMedGoogle ScholarCrossref
31.
Buist  A, Gotman  N, Yonkers  KA.  Generalized anxiety disorder: course and risk factors in pregnancy.  J Affect Disord. 2011;131(1-3):277-283.PubMedGoogle ScholarCrossref
32.
Sheehan  DV, Lecrubier  Y, Sheehan  KH,  et al.  The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10 J Clin Psychiatry. 1998;59(S20)(suppl 20):22-33.PubMedGoogle Scholar
33.
Cox  J, Holden  J.  Perinatal Psychiatry: Use and Misuse of the Edinburgh Postnatal Depression Scale. Glasgow, Scotland: Royal College of Psychiatrists; 1994.
34.
Matthey  S.  Using the Edinburgh Postnatal Depression Scale to screen for anxiety disorders.  Depress Anxiety. 2008;25(11):926-931.PubMedGoogle ScholarCrossref
35.
Cheung  YB.  A modified least-squares regression approach to the estimation of risk difference.  Am J Epidemiol. 2007;166(11):1337-1344.PubMedGoogle ScholarCrossref
36.
Yonkers  KA, Bruce  SE, Dyck  IR, Keller  MB.  Chronicity, relapse, and illness—course of panic disorder, social phobia, and generalized anxiety disorder: findings in men and women from 8 years of follow-up.  Depress Anxiety. 2003;17(3):173-179.PubMedGoogle ScholarCrossref
37.
McElhatton  PR.  The effects of benzodiazepine use during pregnancy and lactation.  Reprod Toxicol. 1994;8(6):461-475.PubMedGoogle ScholarCrossref
38.
Wilbanks  GD, Bressler  B, Peete  CH  Jr, Cherny  WB, London  WL.  Toxic effects of lithium carbonate in a mother and newborn infant.  JAMA. 1970;213(5):865-867.PubMedGoogle ScholarCrossref
39.
Ornoy  A, Arnon  J, Shechtman  S, Moerman  L, Lukashova  I.  Is benzodiazepine use during pregnancy really teratogenic?  Reprod Toxicol. 1998;12(5):511-515.PubMedGoogle ScholarCrossref
40.
Olney  JW, Wozniak  DF, Jevtovic-Todorovic  V, Farber  NB, Bittigau  P, Ikonomidou  C.  Drug-induced apoptotic neurodegeneration in the developing brain.  Brain Pathol. 2002;12(4):488-498.PubMedGoogle ScholarCrossref
41.
Källén  B.  Neonate characteristics after maternal use of antidepressants in late pregnancy.  Arch Pediatr Adolesc Med. 2004;158(4):312-316.PubMedGoogle ScholarCrossref
42.
Chambers  CD, Hernandez-Diaz  S, Van Marter  LJ,  et al.  Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn.  N Engl J Med. 2006;354(6):579-587.PubMedGoogle ScholarCrossref
43.
Oberlander  TF, Warburton  W, Misri  S, Aghajanian  J, Hertzman  C.  Neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitor antidepressants and maternal depression using population-based linked health data.  Arch Gen Psychiatry. 2006;63(8):898-906.PubMedGoogle ScholarCrossref
44.
Viguera  AC, Cohen  LS, Bouffard  S, Whitfield  TH, Baldessarini  RJ.  Reproductive decisions by women with bipolar disorder after prepregnancy psychiatric consultation.  Am J Psychiatry. 2002;159(12):2102-2104.PubMedGoogle ScholarCrossref
Original Investigation
November 2017

Association of Panic Disorder, Generalized Anxiety Disorder, and Benzodiazepine Treatment During Pregnancy With Risk of Adverse Birth Outcomes

Author Affiliations
  • 1Department of Psychiatry, Yale School of Medicine, New Haven, Connecticut
  • 2Department of Obstetrics, Gynecology, and Reproductive Sciences, Yale School of Medicine, New Haven, Connecticut
  • 3Department of Epidemiology and Public Health, Yale School of Medicine, New Haven, Connecticut
JAMA Psychiatry. 2017;74(11):1145-1152. doi:10.1001/jamapsychiatry.2017.2733
Key Points

Question  What is the possible association of anxiety disorders with maternal and fetal outcomes?

Results  In this cohort study of 2654 pregnant women followed up through pregnancy and the postpartum period, neither panic disorder nor generalized anxiety disorder was associated with maternal or neonatal outcomes of interest. With maternal benzodiazepine treatment, rates of ventilatory support increased by 61 of 1000 neonates and duration of gestation was shortened by 3.6 days; with maternal serotonin reuptake inhibitor use, gestation was shortened by 1.8 days, 152 of 1000 additional newborns required minor respiratory interventions, and 53 of 1000 additional women experienced hypertensive diseases of pregnancy.

Meaning  Neither panic disorder nor generalized anxiety disorder increased adverse birth outcomes in this analysis; although antidepressant and benzodiazepine treatment increased some adverse outcomes, the rate for most events was modest.

Abstract

Importance  Registry data show that maternal panic disorder, or anxiety disorders in general, increase the risk for adverse pregnancy outcomes. However, diagnoses from registries may be imprecise and may not consider potential confounding factors, such as treatment with medication and maternal substance use.

Objective  To determine whether panic disorder or generalized anxiety disorder (GAD) in pregnancy, or medications used to treat these conditions, are associated with adverse maternal or neonatal pregnancy outcomes.

Design, Setting, and Participants  This cohort study conducted between July 1, 2005, and July 14, 2009, recruited women at 137 obstetric practices in Connecticut and Massachusetts before 17 weeks of pregnancy and reassessed them at 28 (±4) weeks of pregnancy and 8 (±4) weeks postpartum. Psychiatric diagnoses were determined by answers to the World Mental Health Composite International Diagnostic Interview. Assessments also gathered information on treatment with medications and confounding factors, such as substance use, previous adverse birth outcomes, and demographic factors.

Exposure  Panic disorder, GAD, or use of benzodiazepines or serotonin reuptake inhibitors.

Main Outcomes and Measures  Among mothers: preterm birth, cesarean delivery, and hypertensive diseases of pregnancy. Among neonates: low birth weight, use of minor respiratory interventions, and use of ventilatory support.

Results  Of the 2654 women in the final analysis (mean [SD] age, 31.0 [5.7] years), most were non-Hispanic white (1957 [73.7%]), 98 had panic disorder, 252 had GAD, 67 were treated with a benzodiazepine, and 293 were treated with a serotonin reuptake inhibitor during pregnancy. In adjusted models, neither panic disorder nor GAD was associated with maternal or neonatal complications of interest. Most medication exposures occurred early in pregnancy. Maternal benzodiazepine use was associated with cesarean delivery (odds ratio [OR], 2.45; 95% CI, 1.36-4.40), low birth weight (OR, 3.41; 95% CI, 1.61-7.26), and use of ventilatory support for the newborn (OR, 2.85; 95% CI, 1.2-6.9). Maternal serotonin reuptake inhibitor use was associated with hypertensive diseases of pregnancy (OR, 2.82; 95% CI, 1.58-5.04), preterm birth (OR, 1.56; 95% CI, 1.02-2.38), and use of minor respiratory interventions (OR, 1.81; 95% CI, 1.39-2.37). With maternal benzodiazepine treatment, rates of ventilatory support increased by 61 of 1000 neonates and duration of gestation was shortened by 3.6 days; with maternal serotonin reuptake inhibitor use, gestation was shortened by 1.8 days, 152 of 1000 additional newborns required minor respiratory interventions, and 53 of 1000 additional women experienced hypertensive diseases of pregnancy.

Conclusions and Relevance  Panic disorder and GAD do not contribute to adverse pregnancy complications. Women may require treatment with medications during pregnancy, which can shorten the duration of gestation slightly. Maternal treatment with a serotonin reuptake inhibitor is also associated with hypertensive disease of pregnancy and cesarean delivery.

×